Temocillin for non-urinary tract infections caused by AmpC-producing Enterobacterales: Is it a feasible option?
Year: 2026
Type: article
Abstract: • Evidence pertaining to temocillin in non-urinary AmpC infections is limited. • This study reports on real-life use of temocillin in digestive and respiratory infections. • Clinical cure was achieved in all patients at Day 28. • No relapse or infection-related death occurred. • Temocillin may in selected cases be considered as a carbapenem-sparing option. Infections due to AmpC-producing Enterobacterales represent an increasing therapeutic challenge. Third-generation cephalosporins may select resistant mutants, inducing clinicians to use cefepime or carbapenems and thereby contributing to carbapenem resistance. While temocillin is a narrow-spectrum beta-lactam stable against AmpC enzymes, evidence of its impact in non-urinary tract infections remains limited. We conducted a retrospective study of adult patients treated with temocillin for non-urinary tract infections caused by AmpC-producing Enterobacterales between 2016 and 2021. Clinical, microbiological and therapeutic data were collected. The primary outcome was treatment failure within twenty-eight days. Six patients were included, with a median age of sixty-one years; three required intensive care. Infection sites were digestive or respiratory. All patients had achieved clinical cure by day twenty-eight, without recurrence, infection-related mortality, or adverse events. Having led to favorable outcomes, temocillin may represent a carbapenem-sparing option when in vitro susceptibility is confirmed. These findings call for further evaluation in larger prospective clinical studies.
Source: Infectious Diseases Now
Institutions: Hôpital Raymond-Poincaré, Hanoi Medical University, Hôpital Foch
Language: English
Subfield: Molecular Medicine
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $1,640
OpenAlex ID: W7128795777